CN102335166A - Pharmaceutical composition containing arctigenin and its application - Google Patents
Pharmaceutical composition containing arctigenin and its application Download PDFInfo
- Publication number
- CN102335166A CN102335166A CN2010102358145A CN201010235814A CN102335166A CN 102335166 A CN102335166 A CN 102335166A CN 2010102358145 A CN2010102358145 A CN 2010102358145A CN 201010235814 A CN201010235814 A CN 201010235814A CN 102335166 A CN102335166 A CN 102335166A
- Authority
- CN
- China
- Prior art keywords
- retinoic acid
- aretigenin
- trans
- pharmaceutical composition
- leukemia
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Landscapes
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
The invention relates to a pharmaceutical composition containing arctigenin and an application of the pharmaceutical composition in preparing medicine for treating cancer, especially an application of the pharmaceutical composition in preparing medicine for treating leukemia. The pharmaceutical composition of the invention comprises the active components arctigenin and all-trans retinoic acid. Preferably, according to an amount of substance, in the pharmaceutical composition of the invention, the mol ratio of arctigenin to all-trans retinoic acid is 1:0.01-100. In the pharmaceutical composition, the combination of the active components arctigenin and all-trans retinoic acid has synergetic effect for anti-leukemia.
Description
Technical field
The present invention relates to a kind of pharmaceutical composition and purposes in the medicine of preparation treatment cancer thereof that contains aretigenin, especially the purposes in the leukemic medicine of preparation treatment.
Background technology
At present, cancer is that current serious influences human health, threatens one of principal disease of human life.Cancer constitutes world today's All Countries three big causes of death with cardiovascular and cerebrovascular disease and contingency.Therefore, World Health Organization (WHO) and hygiene department of national governments all classify capture cancer as a top priority as.Treat method for cancer in the world and mainly contain three kinds, the one, adopt surgical excision, removal lesion tissue prevents the cancerous cell diffusion; The 2nd, adopt chemotherapy or radiotherapy, with kill cancer cell; The 3rd, heal with medicine.The method of employing excision has increased patient's misery, hinders its vigour, and expense is huge.With the method for chemotherapy or radiotherapy, in kill cancer cell, also injure erythrocyte and leukocyte, patient suffers untold misery.
Leukemia is the healthy hemopoietic system malignant tumor of serious harm human life, is one type of malignant disease that originates from hemopoietic (or lymph) stem cell.Because stem cell is impaired, the leukaemia loses the ability of further differentiation and maturation, and perhaps increment is uneven with differentiation capability, and stops at cytocerastic different phase, be embodied in cell infinitely increment in vivo, and its differentiation and maturation and apoptosis is obstructed.Therefore, leukemic treatment can be started with from three aspects: cell death inducing, inducing cell differentiation and stem cell transplantation reconstitute hematopoiesis function.Traditional combined chemotherapy is still mainly adopted in leukemic so far treatment, but this therapy side effect is very big, and relapse rate is high, especially immunity of organism and hemopoietic system is had bigger infringement.
Arctiin and aretigenin (Arctigenin; AG) all derive from the dry mature fruit Fructus Arctii of Fructus Arctii; The Arctiin activity is very little, must be that aretigenin just can be absorbed by the body through metabolic conversion, and aretigenin is can be by the direct effective ingredient that absorbs of human body.At present, existing bibliographical information aretigenin has following pharmacologically active: 1) antiinflammatory and immunoregulation effect; 2) antivirus action comprises HIV-1 and influenza virus; 3) effect of inducing apoptosis of tumour cell; 4) nephropathy and diabetes, diabetic complication therapeutical effect; 5) HSR inhibitory action; 6) neuroprotective; 7) blood vessel dilating effect; 8) platelet activating factor antagonism; 9) effect of anti-ageing year dementia; 10) suppress K
+The effect of contracture etc.Such as; Cho J Y; Et al.Immunomodulatory effect of arctigenin; A lignan compound ontumor necrosis factor-α and nitric oxide production, and lymphocyteproliferation [J] .J Pharm Pharmcol.1999; 51 (11): 1267-1273. discloses aretigenin and has had antiinflammatory and immunoregulation effect; Gao Y, et al.Activity of in vitro anti-influenza virus ofarctigenin [J] .Chinese Traditional and Herbal Drugs (Chinese herbal medicine) .2002; 33 (8): 724-726. discloses aretigenin and has had antiviral effect; Kim S H, et al.Hepatoprotectivedibenzylbutyrolactone lignans of Torreya nucifera against CCl4-induced toxicityin primary cultured rat hepatocytes [J] .Biol Pharm Bull.2003; 26 (8): 1202-1205. discloses the effect that aretigenin has inducing apoptosis of tumour cell.
Retinoic acid (retinoic acid; RA) belong to Vitamin A compounds family; Basic structure or biological activity are similar to vitamin A, are made up of cyclohexene, side chain and polar group three parts, are divided into two kinds of isomers because the carboxyl direction is different; Be that (all-trans retinoic acid is ATRA) with cis retinoic acid (cis-RA) for all-trans-retinoic acid.ATRA has wide biological activity, can inducing apoptosis of tumour cell, suppress the propagation of kinds of tumor cells and the differentiation of inducing tumor cell etc.This medicine is mainly used in the hematological system tumor treatment.Clinical data shows that single use ATRA curative effect is more limited comparatively speaking.
Summary of the invention
One of the object of the invention provides a kind of pharmaceutical composition, and said pharmaceutical composition can suppress growth of tumour cell, thereby reaches the effect of treating cancer better.
Pharmaceutical composition of the present invention comprises active component aretigenin and all-trans-retinoic acid.Preferably, by amount of substance, in the pharmaceutical composition of the present invention, the mol ratio of aretigenin and all-trans-retinoic acid is 1: 0.01～100.
Pharmaceutical composition of the present invention; Wherein has the anti-tumor synergetic effect after the associating of active component aretigenin and all-trans-retinoic acid; Promptly not only can suppress the growth of people's acute promyelocytic leukemic NK4 cell and chronic myelocytic leukemia K562 cell; More amazingly be; It can suppress the growth of children's grain leukemia MR-2 cell early of retinoic acid drug resistance, and this result is for acute promyelocytic leukemic, chronic myelocytic leukemia and retinoic acid drug resistance children's morning grain leukemia have deep directive significance clinically.
Need to prove that confirmed in the pharmaceutical composition of the present invention through above in vitro tests, aretigenin and all-trans-retinoic acid have shown surprising concertedness antitumor action.Because pharmaceutical composition of the present invention (mol ratio of aretigenin and all-trans-retinoic acid is 1: 0.01～100) in quite wide scope has the anti-tumor synergetic effect, therefore, can think that improvement of the present invention is component itself.In addition, those skilled in the art also can expect, pharmaceutical composition of the present invention all can be realized the object of the invention in the mol ratio of aretigenin and all-trans-retinoic acid is 1: 0.01～100 scope.
Two of the object of the invention provides the medical usage of chemical compound, specifically, and the purposes of compositions in the medicine of preparation treatment cancer that active component is made up of aretigenin and all-trans-retinoic acid.
Preferred a kind of technical scheme is: the purposes of compositions in the leukemic medicine of preparation treatment that active component is made up of aretigenin and all-trans-retinoic acid.
More preferably a kind of technical scheme is: the purposes of compositions in the medicine of preparation treatment acute promyelocytic leukemic that active component is made up of aretigenin and all-trans-retinoic acid.
More preferably another kind of technical scheme is: the purposes of compositions in the medicine of preparation treatment chronic myelocytic leukemia that active component is made up of aretigenin and all-trans-retinoic acid.
More preferably another kind of technical scheme is: the purposes of compositions in the leukemic medicine of the early young grain of preparation treatment retinoic acid drug resistance that active component is made up of aretigenin and all-trans-retinoic acid.
In the technical scheme of above-mentioned preferred medical usage, by amount of substance, the mol ratio of aretigenin and all-trans-retinoic acid is 1: 0.01～100.
In order clearly to illustrate technique effect of the present invention, the inventor further sets forth the effect of pharmaceutical composition of the present invention at the inhibition growth of tumour cell through following Test Example:
The Test Example compositions is to the test of leukaemia's growth effect:
1. test is divided into groups following with administration administration final concentration:
Blank group: isopyknic excipient
Aretigenin (AG) hangs down the amount group: 0.1 μ mol/L aretigenin
Aretigenin (AG) a large amount group: 10 μ mol/L aretigenins
All-trans-retinoic acid (ATRA) hangs down the amount group: 0.1 μ mol/L all-trans-retinoic acid
All-trans-retinoic acid (ATRA) a large amount group: 10 μ mol/L all-trans-retinoic acids
Compositions A group: 10.0 μ mol/L aretigenins+0.1 μ mol/L all-trans-retinoic acid
Compositions B group: 1.0 μ mol/L aretigenins+1.0 μ mol/L all-trans-retinoic acids
Compositions C group: 0.1 μ mol/L aretigenin+10.0 μ mol/L all-trans-retinoic acids
2. testing program and result add up as follows:
With people's acute promyelocytic leukemic NK4 cell, chronic myelocytic leukemia K562 cell, retinoic acid drug resistance early children's grain leukemia MR-2 cell is inoculated in respectively in the RPMI-1640 culture fluid, contains 5%CO in 37 ℃
2Incubator in cultivate and to go down to posterity, be inoculated in 96 well culture plates, add the medicine of respective concentration during inoculation by group; Parallel 5 holes of every concentration; The MTT reduction reaction is measured inhibition rate of tumor growth behind the 48h, and test data carries out statistical analysis with the Excel system, specifically referring to table 1.
Table 1 compositions is to the influence of leukaemia's growth
Compare with the low amount group of aretigenin,
##P＜0.01;
Compare with aretigenin a large amount group,
*P＜0.01;
Compare with the low amount group of all-trans-retinoic acid,
$P＜0.05,
$$P＜0.01;
Compare with all-trans-retinoic acid a large amount group,
$P＜0.05,
$$P＜0.01
Result through above-mentioned table 1 can find out; Compositions A group, B group are compared with the aretigenin low dose group with the C group has utmost point significant difference (p＜0.01); Compare with the aretigenin high dose group and also to have utmost point significant difference (p＜0.01), compare with two dose groups of all-trans-retinoic acid and have significant difference or utmost point significant difference.This shows; Has the anti-tumor synergetic effect after aretigenin and the all-trans-retinoic acid associating; Promptly not only can suppress the growth of people's acute promyelocytic leukemic NK4 cell and chronic myelocytic leukemia K562 cell; More amazingly be, it can suppress the growth of children's grain leukemia MR-2 cell early of retinoic acid drug resistance, this result for acute promyelocytic leukemic, chronic myelocytic leukemia and retinoic acid drug resistance clinically early children's grain leukemia deep directive significance is arranged.In addition, compare, with the various leukaemias behind the drug effect with negative control group; No matter be K562 cell, NK4 cell; Peculiar morphological feature, i.e. nucleus wrinkle behind the apoptosis can obviously appear in still MR-2 cell; Chromatic agglutination is cracked into and forms the apoptotic body that is held by mould behind the fragment.Moreover some cellular morphology of compositions B group transforms to ripe direction, and cell shows karyopycnosis, and karyoplasmic ratio reduces, characteristics such as kernel minimizing.
The specific embodiment
Below further describe the present invention through the specific embodiment, the present invention is not limited only to following examples.
Embodiment 1 microemulsion
Aretigenin 0.1g
All-trans-retinoic acid 5g
Oleum menthae 35g
Polyoxyethylene-23-lauryl ether 60g
1,2-propylene glycol 30g
Preparation technology: take by weighing recipe quantity Oleum menthae, polyoxyethylene-23-lauryl ether, 1; The 2-propylene glycol; Stir after the mixing, add the dissolving of aretigenin, all-trans-retinoic acid then, also can ultrasonic Treatment with accelerate dissolution; Concentrated solution be must clarify, aretigenin and all-trans-retinoic acid microemulsion concentrate are.Laser granulometry is measured its particle diameter, and mean diameter is 15nm.
Embodiment 2 microemulsions
Aretigenin 2g
All-trans-retinoic acid 2g
Oleum Menthae Rotundifoliae 30g
SY-Glyster MSW 750 55g
1,2-propylene glycol 25g
Preparation technology: take by weighing recipe quantity Oleum Menthae Rotundifoliae, SY-Glyster MSW 750,1; The 2-propylene glycol; Stir after the mixing, add the dissolving of aretigenin, all-trans-retinoic acid then, also can ultrasonic Treatment with accelerate dissolution; Concentrated solution be must clarify, aretigenin and all-trans-retinoic acid microemulsion concentrate are.Laser granulometry is measured its particle diameter, and mean diameter is 15nm.
Embodiment 3 microemulsions
Aretigenin 10g
All-trans-retinoic acid 0.5g
Oleum menthae 40g
Sad ethyl oleate 55g
1,2-propylene glycol 45g
Polyethylene Glycol 8000 55g
Preparation technology: take by weighing recipe quantity Oleum menthae, sad ethyl oleate, 1; 2-propylene glycol, Polyethylene Glycol 8000; Stir after the mixing, add aretigenin dissolving then, also can ultrasonic Treatment with accelerate dissolution; Concentrated solution be must clarify, aretigenin and all-trans-retinoic acid microemulsion concentrate are.Laser granulometry is measured its particle diameter, and mean diameter is 40nm.
Embodiment 4 microemulsions
Aretigenin 5g
All-trans-retinoic acid 1g
Oleum menthae 40g
Sad ethyl oleate 55g
1,2-propylene glycol 45g
Polyethylene Glycol 3350 40g
Preparation technology: take by weighing recipe quantity Oleum menthae, sad ethyl oleate, 1; 2-propylene glycol, Polyethylene Glycol 3350; Stir after the mixing, add aretigenin dissolving then, also can ultrasonic Treatment with accelerate dissolution; Concentrated solution be must clarify, aretigenin and all-trans-retinoic acid microemulsion concentrate are.Laser granulometry is measured its particle diameter, and mean diameter is 40nm.
Embodiment 5 microemulsions
Aretigenin 1g
All-trans-retinoic acid 0.1g
Hydrogenation cocos nucifera oil glyceride 5g
Lauroyl Polyethylene Glycol-32-glyceride 20g
1,2-propylene glycol 5g
Polyethylene Glycol 3350 20g
Preparation technology: take by weighing recipe quantity hydrogenation cocos nucifera oil glyceride, lauroyl Polyethylene Glycol-32-glyceride, 1; 2-propylene glycol, Polyethylene Glycol 3350; Stir after the mixing, add aretigenin dissolving then, also can ultrasonic Treatment with accelerate dissolution; Concentrated solution be must clarify, aretigenin and all-trans-retinoic acid microemulsion concentrate are.Laser granulometry is measured its particle diameter, and mean diameter is 40nm.
Embodiment 6 microemulsions
Aretigenin 0.6g
All-trans-retinoic acid 0.4g
Lauroyl Polyethylene Glycol-32-glyceride 20g
Polyoxyethylene castor oil EL-40 35g
1,2-propylene glycol 15g
Preparation technology: take by weighing recipe quantity lauroyl Polyethylene Glycol-32-glyceride, polyoxyethylene castor oil EL-40,1; The 2-propylene glycol; Stir after the mixing, add the dissolving of aretigenin, all-trans-retinoic acid then, also can ultrasonic Treatment with accelerate dissolution; Concentrated solution be must clarify, aretigenin and all-trans-retinoic acid microemulsion concentrate are.Laser granulometry is measured its particle diameter, and mean diameter is 15nm.
Embodiment 7 injections
Aretigenin 0.1g
All-trans-retinoic acid 1g
Injection soybean oil 18g
Glycerol 2.6g
Soybean lecithin 1.5g
Water for injection adds to 100ml
Preparation technology: with soybean lecithin, glycerol, be scattered in the 60ml water for injection, with aretigenin, all-trans-retinoic acid and injection soybean oil mix homogeneously, be mixed with oil phase again; Then oil phase is joined aqueous phase, the limit edged stirs, evenly the ultrasonic 1h in back; Be settled to 100ml with water for injection afterwards, after change the high pressure dispersing emulsification machine over to, emulsifying 30min; Fill, sterilization promptly gets.
Embodiment 8 injections
Aretigenin 2.0g
All-trans-retinoic acid 0.5g
Injection soybean oil 18g
Glycerol 2.0g
Propylene glycol 5.0g
Soybean lecithin 1.5g
Water for injection adds to 100ml
Preparation technology: earlier soybean lecithin, glycerol, propylene glycol are scattered in the 60ml water for injection, with aretigenin, all-trans-retinoic acid and injection soybean oil mix homogeneously, are mixed with oil phase again; Then oil phase is joined aqueous phase, the limit edged stirs, evenly the ultrasonic 1h in back; Be settled to 100ml with water for injection afterwards, after change the high pressure dispersing emulsification machine over to, emulsifying 30min; Fill, sterilization promptly gets.
Embodiment 9 tablets
Aretigenin 8.0g
All-trans-retinoic acid 5.0g
Starch 80g
Dextrin 150.0g
Low-substituted hydroxypropyl cellulose 10.0g
60% ethanol is an amount of
Magnesium stearate 2.0g
Preparation technology: take by weighing aretigenin, all-trans-retinoic acid, starch, dextrin, low-substituted hydroxypropyl cellulose mix homogeneously.Other gets in an amount of 60% ethanol adding mixed-powder, mix homogeneously, and the system soft material is processed wet granular through 18 mesh sieves, and is dry about 60 ℃, with 20 mesh sieve granulate, adds magnesium stearate, mixing, tabletting promptly gets.
Embodiment 10 tablets
Aretigenin 0.1g
All-trans-retinoic acid 10g
Starch 80g
Dextrin 150.0g
Low-substituted hydroxypropyl cellulose 10.0g
60% ethanol is an amount of
Magnesium stearate 2.0g
Preparation technology: take by weighing all-trans-retinoic acid, starch, dextrin, low-substituted hydroxypropyl cellulose mix homogeneously earlier, use the equivalent incremental method even then aretigenin and above powder mixes.Other gets in an amount of 60% ethanol adding mixed-powder, mix homogeneously, and the system soft material is processed wet granular through 18 mesh sieves, and is dry about 60 ℃, with 20 mesh sieve granulate, adds magnesium stearate, mixing, tabletting promptly gets.
Embodiment 11 capsules
Aretigenin 50g
All-trans-retinoic acid 1g
Starch 80g
Micropowder silica gel 10g
Preparation technology: take by weighing aretigenin, starch, micropowder silica gel mix homogeneously earlier, use the equivalent incremental method even all-trans-retinoic acid and above powder mixes then, filling capsule promptly gets.
Embodiment 12 granules
Aretigenin 50g
All-trans-retinoic acid 1g
Lactose 160g
Sucrose 60g
Soluble starch 450g
8% starch slurry is an amount of
Preparation technology: each adjuvant in will writing out a prescription is crossed 100 mesh sieves, take by weighing aretigenin and all-trans-retinoic acid and soluble starch, lactose and sucrose mix homogeneously after, add 8% starch slurry system soft material; 18 mesh sieves are granulated, in 60 ℃ of dryings, and 16 mesh sieve granulate; Pack promptly gets.
Claims (9)
1. pharmaceutical composition, it is characterized in that: it contains active component aretigenin and all-trans-retinoic acid.
2. pharmaceutical composition as claimed in claim 1 is characterized in that: by amount of substance, the mol ratio of aretigenin and all-trans-retinoic acid is 1: 0.01～100.
3. pharmaceutical composition as claimed in claim 1 is characterized in that: it is microemulsion, injection, tablet, capsule, granule.
4. the purposes of compositions in the medicine of preparation treatment cancer formed by aretigenin and all-trans-retinoic acid of active component.
5. purposes as claimed in claim 4 is characterized in that: described cancer is a leukemia.
6. purposes as claimed in claim 5 is characterized in that: described leukemia is an acute promyelocytic leukemic.
7. purposes as claimed in claim 5 is characterized in that: described leukemia is a chronic myelocytic leukemia.
8. purposes as claimed in claim 5 is characterized in that: described leukemia is retinoic acid drug resistance children's grain leukemia early.
9. like the arbitrary described purposes of claim 5-8, it is characterized in that: by amount of substance, the mol ratio of aretigenin and all-trans-retinoic acid is 1: 0.01～100.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201010235814.5A CN102335166B (en) | 2010-07-15 | 2010-07-15 | Pharmaceutical composition containing arctigenin and its application |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201010235814.5A CN102335166B (en) | 2010-07-15 | 2010-07-15 | Pharmaceutical composition containing arctigenin and its application |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN102335166A true CN102335166A (en) | 2012-02-01 |
| CN102335166B CN102335166B (en) | 2014-12-31 |
Family
ID=45511269
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201010235814.5A Active CN102335166B (en) | 2010-07-15 | 2010-07-15 | Pharmaceutical composition containing arctigenin and its application |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102335166B (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106163515A (en) * | 2014-04-10 | 2016-11-23 | 客乐谐制药株式会社 | Anticancer and agents for relieving side effects |
| CN108721630A (en) * | 2017-04-19 | 2018-11-02 | 三凡生技研发股份有限公司 | Vehicle for dispersing hydrophobic plant extracts |
| CN109718210A (en) * | 2017-10-31 | 2019-05-07 | 鲁南制药集团股份有限公司 | A kind of arctigenin preparation |
-
2010
- 2010-07-15 CN CN201010235814.5A patent/CN102335166B/en active Active
Non-Patent Citations (4)
| Title |
|---|
| TOSHIHIKO HIRANO，ET AL: "NATURAL FLAVONOIDS AND LIGNANS ARE POTENT CYTOSTATIC AGENTS AGAINST HUMAN LEUKEMIC HL-60 CELLS", 《LIFE SCIENCES》 * |
| 王潞，等: "牛蒡子苷元诱导人白血病细胞凋亡的作用及机制", 《药学学报》 * |
| 王潞，等: "牛蒡子苷及牛蒡子苷元的药理作用研究进展", 《中草药》 * |
| 顾伟英，等: "全反式维甲酸治疗急性早幼粒细胞白血病过程血脂变化的研究", 《肿瘤》 * |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106163515A (en) * | 2014-04-10 | 2016-11-23 | 客乐谐制药株式会社 | Anticancer and agents for relieving side effects |
| CN108721630A (en) * | 2017-04-19 | 2018-11-02 | 三凡生技研发股份有限公司 | Vehicle for dispersing hydrophobic plant extracts |
| CN109718210A (en) * | 2017-10-31 | 2019-05-07 | 鲁南制药集团股份有限公司 | A kind of arctigenin preparation |
Also Published As
| Publication number | Publication date |
|---|---|
| CN102335166B (en) | 2014-12-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102440986B (en) | Application of arctigenin in preparation of medicines for preventing and treating bone marrow suppression caused by radiation or chemicals | |
| CN105963637B (en) | Application of cryptotanshinone and curcumin in preparation of tumor treatment medicine | |
| CN101239081A (en) | Composition for treating cancer and preparation thereof | |
| CN105362340B (en) | A kind of pharmaceutical composition for treating leukaemia and preparation method thereof | |
| CN102335166B (en) | Pharmaceutical composition containing arctigenin and its application | |
| CN104546823A (en) | Application of anhydroicaritin in preparing drug for treating or preventing thrombopenia | |
| CN105796638B (en) | Application of oridonin and cryptotanshinone in preparation of leukemia treatment drug | |
| CN105982887A (en) | Application of arctigenin in preparing medicine for treating blood hyperviscosity | |
| CN102370645A (en) | Anticancer drug composition | |
| CN103919850B (en) | A kind of pharmaceutical composition and its application in antineoplastic is prepared | |
| CN103027906A (en) | Application of arctigenin in treating anemia | |
| CN102397548B (en) | Medicinal composition containing arctigenin and medical application thereof | |
| CN102526024A (en) | Anticancer pharmaceutical composition | |
| CN103127093A (en) | Application of arctigenin in preparation of medicine for curing or preventing brain glioma | |
| CN105833173B (en) | Application of oridonin and curcumin in preparation of medicament for treating leukemia | |
| US20060177520A1 (en) | Compositions and methods for reducing cytotoxicity and inhibiting angiogenesis | |
| CN102151275A (en) | Pancreatic cancer-resisting effect of oleanolic acid and pharmaceutical preparation of oleanolic acid | |
| CN102133219A (en) | Anti-cervical cancer effect of oleanolic acid and pharmaceutical preparation thereof | |
| CN102940683B (en) | Chinese medicinal compound composition for treating liver cancer and preparation method thereof | |
| CN101773546A (en) | Salvia miltiorrhiza effective-component synchronous site-specific drug delivery mini-pill and preparation method thereof | |
| CN1943677A (en) | A Chinese traditional medicinal composition and its preparation method | |
| CN102091078A (en) | Maslinic acid anti-hepatocarcinoma effect and maslinic acid medicinal preparation | |
| Chang et al. | Experimental study on growth inhibition against anaplastic thyroid carcinoma of animal model by application of ginsenoside Rg1 | |
| CN102106860A (en) | Anti-liver-cancer effect of Oleanolic acid and pharmaceutic preparation | |
| CN101628050B (en) | Traditional Chinese medicine preparation for treating prostate gland diseases and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant |